Anti-IL-8 antibody activates myeloid cells and potentiates the anti-tumor activity of anti-PD-1 antibody in the humanized pancreatic cancer murine model

Pancreatic ductal adenocarcinoma(PDAC) does not respond to single-agent immune checkpoint inhibitor therapy, including anti-PD-1 antibody(aPD-1) therapy. Higher plasma levels of IL-8 are associated with poorer outcomes in patients who receive aPD-1 therapies, providing a rationale for combination im...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Pan, Rozich, Noah, Wang, Jianxin, Wang, Junke, Xu, Yao, Herbst, Brian, Yu, Raymond, Muth, Stephen, Niu, Nan, Li, Keyu, Funes, Vanessa, Gai, Jessica, Osipov, Arsen, Edil, Barish H., Wolfgang, Christopher L., Lei, Ming, Liang, Tingbo, Zheng, Lei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9485862/
https://www.ncbi.nlm.nih.gov/pubmed/35533951
http://dx.doi.org/10.1016/j.canlet.2022.215722

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9485862/
https://www.ncbi.nlm.nih.gov/pubmed/35533951
http://dx.doi.org/10.1016/j.canlet.2022.215722

Ejemplares similares